Milestone and Royalty Payments. Payments As consideration for the licenses and rights granted in this Agreement, Abboxx xxxll make milestone payments to RiboGene, by Product for human pharmaceutical use in the Field, for development of such Product by Abboxx, Xxboxx Xxxiliate or Abboxx xxxlicensee for such human pharmaceutical purposes, as follows:
Milestone and Royalty Payments. 9.1 Nucana agrees to make milestone payments to UC3 as set forth in Schedule 2. Each milestone payment is owed whether the milestone is achieved by Nucana, an Affiliate, Licensee or Assignee. Nucana shall inform UC3 within [***] of the event and the payment shall be made within [***] of the notice of each event being served to UC3. If the milestone is achieved by a Licensee or Assignee, Nucana shall inform UC3 within [***] of Nucana’s knowledge of the event and payment shall be made within [***] of notice of each event being served to UC3.
9.2 Nucana will pay to UC3 a royalty of [***] percent ([***]%) of Net Sales of Nucana or any of its Affiliates.
9.3 Nucana will pay to UC3 a royalty of [***] percent ([***]%) of all Other Income received by Nucana or any of its Affiliates from the exploitation of the Results and/or Foreground Intellectual Property.
9.4 [***]
9.5 Within [***] of the end of the period commencing on the Effective Date and ending on [***] and each subsequent period of [***] commencing on [***] (each a “Royalty Period”), Nucana shall submit to UC3 a written statement detailing:
(a) the total Net Sales (if any) of Nucana and all its Affiliates during such Royalty Period;
(b) the total royalties payable pursuant to the provisions of clause 9.2 above in respect of such Net Sales;
(c) the total Other Income (if any) received by Nucana and all its Affiliates during such Royalty Period from the exploitation of the Results and/or Foreground Intellectual Property; and
(d) the total royalties payable pursuant to the provisions of Clause 9.3 above in respect of such Other Income together with payment of the total amount of royalties (if any) shown on such statement.
9.6 All sums payable under this Agreement are exclusive of value added tax which shall, if applicable, be payable in addition at the rate in force from time to time.
9.7 Nucana shall and shall procure that each of its Affiliates shall keep true and accurate records and books of account of:
(a) all sales by Nucana or (as the case may be) the relevant Affiliate of Products; and
(b) all proceeds received by Nucana or (as the case may be) the relevant Affiliate from;
(i) Licensees in connection with a licence or sub-licence of the Results or Foreground Intellectual Property, including but not limited to signing or upfront fees, annual licence maintenance fees, royalties on sales and annual minimum royalty payments; and/or
(ii) Assignees in connection with assignation of the Results and/or Foreg...
Milestone and Royalty Payments. (a) Clinical Trial Milestone Payment.
Milestone and Royalty Payments. As partial consideration for the rights granted to Egalet hereunder, Egalet shall make the following payments to Acura:
Milestone and Royalty Payments. Where applicable, the Client shall pay to BioFocus the success fees, milestone payments, royalties and other payments described in that Schedule of Work. Any such payments due under a Schedule of Work are payable to BioFocus by the Client within 30 days of such payment becoming due.
Milestone and Royalty Payments. Section 4.29 of the Company Disclosure Letter contains a complete and accurate list of (a) all milestone, development or similar payments, both scheduled and unscheduled, and (b) all royalty or similar payments (including applicable percentages), in each case, which remain outstanding as of the date hereof, and the applicable time or trigger event upon which each such payment will be made and the product candidates to which such payments relate.
Milestone and Royalty Payments. In further consideration of the rights granted to MTPC under this Agreement, MTPC shall pay to ADCT the following amounts:
Milestone and Royalty Payments. The following new Section 5.8 shall be added immediately after Section 5.7 of the Employment Agreement:
Milestone and Royalty Payments. Employer will pay to Employee during the lifetime of Employee and thereafter to Employee’s heirs or legatees, as applicable, an amount equal to ten percent (10%) of the sum of the gross milestone payments and gross royalty payments received by Employer (or its successor or assigns) from Orphazyme A/S (or its successor or assigns) in respect of Arimoclomol and the covered diseases of (i) Nxxxxxx-Pick disease Type C (NPC), (ii) Amyotrophic Lateral Sclerosis (ALS), (iii) Gaucher disease, (iv) Sporadic Inclusion Body Myositis (sIBM), and (v) any other diseases where Arimoclomol is used, including in combination with another molecular entity, in each case, following the sale of certain assets relating to Employer’s molecular chaperone regulation technology to Orphazyme A/S (f/k/a Orphazyme ApS), as determined pursuant to the terms of that certain Asset Purchase Agreement by and between Employer and Orphazyme ApS, dated May 13, 2011, less applicable tax withholdings; provided, that each such payment shall be made during, but no later than the 15th day of, the calendar month immediately following the calendar month during which such milestone payments and royalty payments are received by Employer (or its successor or assigns) (with the first such payment that is due no later than December 15, 2019 to consist of the cumulative amount that would have otherwise been payable to Employee hereunder during the period commencing on the closing date of the transactions contemplated by such Asset Purchase Agreement and ending on November 30, 2019). The payments under this Section 5.8 are intended to comply with Treas. Reg. Section 1.409A-3(i)(1)(iii) and the provisions hereof shall be interpreted and construed consistently with such intent.”
Milestone and Royalty Payments. In consideration of the rights conferred on Lundbeck herein, including the licenses and sublicenses granted to Intellectual Property owned or Controlled by Myriad, including certain patents and know-how in-licensed from Encore, and Mayo, and for research and development costs incurred by Myriad, Lundbeck shall make the payments provided for herein.
